Preclinical Characterization of Prosetin, a Brain-Penetrant MAP4K Inhibitor for Treating ALS

Pharmacology, Toxicology and Pharmaceutical Science

1. Biological Marker 20%
2. Clinical Trial 100%
3. Contract Research Organization 20%
4. Disease 20%
5. Drug Development 60%
6. Drug Screening 20%
7. Mitogen Activated Protein Kinase Kinase Kinase 20%
8. Mouse Model 20%
9. Neuroprotection 20%
10. Pharmacodynamics 40%
11. Pharmacokinetics 40%
12. Phosphotransferase 20%
13. Preclinical Study 40%
14. Tolerability 20%